Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 0.36 |
| ▸ | DRD2 | P14416 | 5/20 | 0.36 |
| ▸ | DRD4 | P21917 | 5/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | PDE1A | P54750 | 1/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 7/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21404497 | 0.93 | BRD4 (0.36) | HTR1ADRD2DRD4BRD4KCNH2 | |
| SCHEMBL21404358 | 0.86 | MTNR1A (0.37) | KCNH2MTNR1ANAMPTESR1 | |
| SCHEMBL21419117 | 0.84 | JAK2 (0.38) | DRD2 | |
| SCHEMBL21404569 | 0.83 | KCNH2 (0.37) | KCNH2MTNR1AESR1 | |
| SCHEMBL21432777 | 0.82 | PDE1C (0.34) | BRD4KCNH2PDE1APDE1BPDE1C | |
| SCHEMBL21419183 | 0.78 | JAK2 (0.39) | DRD2 | |
| SCHEMBL21404386 | 0.71 | HTR1A (0.37) | HTR1ADRD2DRD4KCNH2PDE1A | |
| SCHEMBL26385227 | 0.71 | EPHX1 (0.42) | DRD2NAMPT | |
| SCHEMBL3038961 | 0.70 | ALDH1A1 (0.51) | MTNR1ANAMPT | |
| SCHEMBL21419084 | 0.69 | EPHX1 (0.43) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11058688-B2 | Imidazopiperazine inhibitors of transcription activating proteins | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-07-13 | — | — | US | disclosed |
| EP-3773587-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | Board of Regents, The University of Texas System (US) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019191667-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-10-03 | — | — | WO | disclosed |
| US-20190298729-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11058688-B2 | Imidazopiperazine inhibitors of transcription activating proteins | EP300, CREBBP, RBBP7 | HTR1A 4334/4885DRD2 4798/4885DRD4 4752/4885 |
| US-20190298729-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | EP300, CREBBP, RBBP7 | HTR1A 4334/4885DRD2 4798/4885DRD4 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.